Treatment of inflammatory bowel disease with 6-mercaptopurine
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsVered Rosenberger, Brenda Kolatch, Linda Susan Marshall, Anna Hotovely-Salomon
Life of this patent
Estimating the term…
Abstract
Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects.
Claims21
1-50. (canceled)
A method of treating a human patient afflicted by Crohn's disease without causing clinically significant liver enzyme elevation, the method comprising administering to the human patient a delayed release pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of 6-MP once per day for a period of time sufficient to treat the human patient without causing clinically significant liver enzyme elevation.
A method of inducing remission or maintaining remission in a human patient afflicted by Crohn's disease, the method comprising administering to the human patient a delayed release pharmaceutical composition comprising a pharmaceutically acceptable carrier and 80 mg of 6-MP once per day for a period of time sufficient to induce or maintain local mucosal healing in the human patient.
A method of treating a human patient suffering from Crohn's disease (CD) who is receiving administration of a steroid, the method comprising adjunctively periodically administering to the human patient a delayed release pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of 6-mercaptopurine (6-MP) effective to treat the human patient.
Dependencies are inferred from the claim text.